We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Assay Monitors Cardiomyopathy in Chagas Disease

By LabMedica International staff writers
Posted on 08 Mar 2011
A serum assay for a protein in the blood has been used to monitor damage to the heart in patients with chronic Chagas disease. More...


A highly sensitive assay for measuring the protein biomarker, cardiac troponin T (cTnT), has been used to assess heart injury in patients suffering from the tropical disease caused by the blood-borne protozoan parasite, Trypanosoma cruzi.

In an international study carried out at the Charité University Hospital, (Berlin, Germany), serum cTnT was measured in 26 healthy subjects and in 179 patients with chronic Chagas disease, of whom 86 were asymptomatic, 71 were suffering from cardiomyopathy with or without megacolon, and 22 were suffering from megacolon exclusively. Megacolon is an abnormal dilation of the colon is often accompanied by a paralysis of the peristaltic movements of the bowel.

For serum cTnT measurement, the conventional, fourth-generation assay and the highly sensitive assay provided by Roche Diagnostics GmbH (Mannheim, Germany), were performed using Roche's Elecsys-2010 chemistry analyzer. Serum cTnT was significantly higher in patients with cardiomyopathy with or without megacolon than in healthy subjects, asymptomatic subjects, and patients with megacolon, and the cTnT value was correlated with the severity of the cardiomyopathy. The lower limit of detection for the highly sensitive assay, was 3 ng/L, and was best at distinguishing patients with, and without, heart injury. C-reactive protein and interleukin 6 were found to parallel cTnT changes in both the different Chagas groups and the cardiomyopathy groups separated by disease severity.

The authors commented that the introduction of cardiac troponin immunoassays with improved sensitivity enables the mirroring of minor, but distinct, cardiac troponin elevations with diagnostic and prognostic effect in pathophysiological conditions of the heart, such as inflammation and cardiomyopathy. With the highly sensitive cTnT assay, a diagnostic tool is now available that supplies data usable in chronic Chagas disease for diagnosis, prognosis, and monitoring of cardiomyopathy. The cTnT measurement could, in their view, supplement electrocardiography, echocardiography, and radiological imaging in patients with chronic Chagas disease, and in special circumstances, be applied before these other diagnostic tools. The study was published in February 2011, in the Archives of Pathology and Laboratory Medicine.

Related Links:

Charité University Hospital
Roche Diagnostics



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.